Follow on Google News News By Tag * Pharmaceutical * Healthcare * Ratings * IP * Fta * Medical * Insurance * Additionally * Cpi * Laboratorios * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News | New Market Research Report: Colombia Pharmaceuticals & Healthcare Report Q3 2010New Healthcare market report from Business Monitor International: "Colombia Pharmaceuticals & Healthcare Report Q3 2010"
On the economic and political fronts, Colombia's economic recovery remains fragile. Without easy access to credit for local consumers and businesses, we see little chance of this picture changing over the coming months, meaning Colombian policymakers are set to remain accommodative for much longer than many regional peers. The domestic inflationary outlook appears benign at present, with year-on-year (y-o-y) consumer price index (CPI) growth dropping to just 1.84% in March, from 2.10% at the start of the year. As month-on-month (m-o-m) inflation is likely to have already peaked this year, returning to a disinflationary trend from May onwards, CPI will have a smaller role in the development of the country's pharmaceutical market. There is now a very real chance that a centrist Partido Verde Colombiano candidate will become the next president of Colombia. We would then envisage a more cooperative approach to regional issues than has been demonstrated by President Alvaro Uribe's centre-right, conservative administration. However, given that we do not expect a significant shift away from Uribe's generally business-friendly reforms, and certainly do not anticipate a ChAvez-style Bolivarian revolution, there is unlikely to be any long-term damage to Colombia's investment environment. On the contrary, closer regional cooperation could help the economy diversify away from its overdependence on exports to the US and Venezuela, a distinct positive for the economic outlook. In fact, Panama and Colombia are in the midst of discussing the conditions of a Free Trade Agreement (FTA), which, if finalised, would have a positive effect on their pharmaceutical manufacturing outputs. With firms given an additional incentive to export regionally, economies of scale and lower prices could be a long-term outcome. Additionally, the move highlights Colombia's efforts to diversify its export destinations. However, Colombia's FTA with the US, penned in 2006, remains low on the list of US administration's priority for 2010. For more information or to purchase this report, go to: - http://www.fastmr.com/ Partial Table of Contents: SWOT Analysis - Colombia Pharmaceutical And Healthcare Industry SWOT - Colombia Political SWOT Analysis - Colombia Economic SWOT Analysis - Colombia Business Environment SWOT Analysis Pharmaceutical Business Environment Ratings - Table: Americas - Regional Pharmaceutical Business Environment Ratings, Q310 - Limits to Potential Returns - Risks To Realisation Of Returns Colombia - Market Summary - Regulatory Regime - Intellectual Property Environment - IP Shortcomings - Counterfeit Pharmaceuticals - Proposed US Free Trade Agreement - Table: Colombia-US FTA Mechanisms Relevant To IP - Pricing and Reimbursement Issues - Other Regulatory Issues Industry Developments - Epidemiology - Recent Public Health Developments - Healthcare Sector - Healthcare Insurance - Private Health Insurance - Healthcare Insurance Funding - Emergency Healthcare Reform - Medical Tourism - Pharmaceutical Retail - Clinical Trials - Medical Devices Industry Forecast Scenario - Overall Market Forecast - Key Growth Factors - Industry - Key Growth Factors - Macroeconomic - Table: Columbia - Economic Activity - Prescription Market Forecasts - Patented Drug Market Forecast - Generic Drug Market Forecast - OTC Medicine Market Forecast - Medical Device Market Forecast - Pharmaceutical Trade Forecast - Other Healthcare Data Forecasts - Key Risks to BMI's Forecast Scenario Competitive Landscape - Pharmaceutical Industry - Domestic Sector - Foreign Sector - Recent Pharmaceutical Company Developments Company Monitor - Indigenous Manufacturers - Tecnoquimicas - Lafrancol - Laboratorios Genfar SA - Laboratorios Brussie - Leading Multinationals - GlaxoSmithKline (GSK) - Pfizer - Merck & Co - Sanofi-Aventis - Novartis Country Snapshot: Colombia Demographic Data - Section 1: Population - Table: Demographic Indicators, 2005-2030 - Table: Rural/Urban Breakdown, 2005-2030 - Section 2: Education And Healthcare - Table: Education, 2002-2005 - Table: Vital Statistics, 2005-2030 - Table: Employment Indicators, 2001-2006 - Full Table of Contents is available at: -- http://www.fastmr.com/ About Business Monitor International Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports. View more research from Business Monitor International at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number